Principal Financial Group Inc. Has $32.19 Million Stock Position in Glaukos Corporation (NYSE:GKOS)

Principal Financial Group Inc. grew its position in Glaukos Corporation (NYSE:GKOS - Free Report) by 21.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 327,036 shares of the medical instruments supplier's stock after purchasing an additional 58,502 shares during the quarter. Principal Financial Group Inc. owned approximately 0.57% of Glaukos worth $32,187,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. State of Wyoming lifted its holdings in shares of Glaukos by 2.3% in the fourth quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier's stock worth $487,000 after buying an additional 72 shares in the last quarter. Quadrant Capital Group LLC grew its holdings in Glaukos by 3.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier's stock worth $345,000 after acquiring an additional 73 shares in the last quarter. Mutual of America Capital Management LLC raised its position in shares of Glaukos by 1.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock valued at $1,252,000 after purchasing an additional 89 shares during the last quarter. HighTower Advisors LLC raised its position in Glaukos by 2.8% during the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock worth $495,000 after buying an additional 91 shares during the last quarter. Finally, Stifel Financial Corp boosted its stake in Glaukos by 2.6% during the 4th quarter. Stifel Financial Corp now owns 4,341 shares of the medical instruments supplier's stock worth $651,000 after purchasing an additional 111 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Stock Performance

GKOS stock traded down $2.87 during trading on Friday, reaching $103.68. 660,520 shares of the company's stock were exchanged, compared to its average volume of 742,471. Glaukos Corporation has a 1-year low of $77.10 and a 1-year high of $163.71. The company has a quick ratio of 5.62, a current ratio of 6.49 and a debt-to-equity ratio of 0.09. The company's fifty day moving average price is $97.18 and its 200-day moving average price is $114.43. The firm has a market cap of $5.92 billion, a PE ratio of -43.75 and a beta of 0.82.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. The business had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative return on equity of 10.66% and a negative net margin of 31.40%. Glaukos's revenue was up 24.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.70) earnings per share. On average, research analysts expect that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on GKOS. Mizuho reduced their price objective on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday, April 16th. Stifel Nicolaus cut their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Wells Fargo & Company lowered Glaukos from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $160.00 to $86.00 in a research note on Thursday, May 1st. Stephens decreased their price target on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Finally, Morgan Stanley dropped their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $134.67.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.